ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Prana Biotechnology Ltd Sponsored ADR (PRAN) Report Updated: Aug 18, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Prana Biotechnology Ltd Sponsored ADR (PRAN)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Biotechnology
Competitors: ENTA, CBPO, DYAX, GNVC

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: C down downgrade
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

Prana Biotechnology Ltd Sponsored ADR© quotemedia

Company Profile

Prana Biotechnology Limited engages in the research and development of therapeutic drugs for the treatment of neurological disorders in Australia. The company primarily focuses on the Alzheimer‘s, Parkinson‘s, and Huntington‘s diseases, as well as various cancer, age-related macular degeneration and cataract, Motor Neuron, and Creutzfeldt-Jakob diseases. Its development stage product line comprises PBT2, a Phase IIb clinical trial product for the treatment of Alzheimer’s disease; and PBT2, a Phase IIa clinical trial product for the treatment of Huntington’s disease. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.

Recent News: Prana Biotechnology Ltd Sponsored ADR